Direct growth‐inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA‐mediated mechanism

[1]  S. H. Young,et al.  Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1. , 2015, American journal of physiology. Cell physiology.

[2]  Soken Tsuchiya,et al.  Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. , 2015, Biochimica et biophysica acta.

[3]  Huamin Wang,et al.  Combined Targeting of STAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer , 2014, Clinical Cancer Research.

[4]  Aune Moro,et al.  miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. , 2013, Biochemical and biophysical research communications.

[5]  K. Iwatsubo,et al.  The Prostanoid EP4 Receptor and Its Signaling Pathway , 2013, Pharmacological Reviews.

[6]  Yanping Zhang,et al.  Increased Th17 Cells in the Tumor Microenvironment Is Mediated by IL-23 via Tumor-Secreted Prostaglandin E2 , 2013, The Journal of Immunology.

[7]  R. Hwang,et al.  Prostaglandin E2 Regulates Pancreatic Stellate Cell Activity Via the EP4 Receptor , 2013, Pancreas.

[8]  R. Hwang,et al.  PGE2 Regulates Pancreatic Stellate Cell Activity Via The EP4 Receptor , 2013 .

[9]  X. Dai,et al.  Involvement of COX-2/PGE2 Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer , 2011, Gastroenterology research and practice.

[10]  Hiroki Takahashi,et al.  Cyclooxygenase-2 Confers Growth Advantage to Syngeneic Pancreatic Cancer Cells , 2011, Pancreas.

[11]  Jonathan C. King,et al.  Loss of 15-Hydroxyprostaglandin Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumors , 2010, Pancreas.

[12]  D. Fitzgerald,et al.  Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer , 2009, BMC Cancer.

[13]  V. Go,et al.  Expression Analysis of the Prostaglandin E2 Production Pathway in Human Pancreatic Cancers , 2008, Pancreas.

[14]  H. Reber,et al.  Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. , 2008, Surgery.

[15]  H. Reber,et al.  Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. , 2007, Cancer research.

[16]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[17]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[18]  A. C. Williams,et al.  Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. , 2006, Biochimica et biophysica acta.

[19]  M. Pino,et al.  Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells , 2005, Cancer biology & therapy.

[20]  D. Bar-Sagi,et al.  Ras Oncogene and Inflammation: Partners in Crime , 2005, Cell cycle.

[21]  L. Boros,et al.  Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. , 2005, Cancer research.

[22]  M. Hull,et al.  Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? , 2004, Molecular cancer therapeutics.

[23]  H. Reber,et al.  PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. , 2003, Biochemical and biophysical research communications.

[24]  J. Regan,et al.  Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? , 2003, Trends in pharmacological sciences.

[25]  M. Wente,et al.  The Selective Cyclooxygenase-2 Inhibitor Nimesulide Induces Apoptosis in Pancreatic Cancer Cells Independent of COX-2 , 2003, Pancreas.

[26]  M. Dohadwala,et al.  Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in Cyclooxygenase-2-dependent Invasion* , 2002, The Journal of Biological Chemistry.

[27]  P. Stork,et al.  Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. , 2002, Trends in cell biology.

[28]  B. Evers,et al.  Inflammation and the development of pancreatic cancer. , 2002, Surgical oncology.

[29]  C. Coscia,et al.  Diversity of G Protein-Coupled Receptor Signaling Pathways to ERK/MAP Kinase , 2002, Neurosignals.

[30]  A. Levine,et al.  Prostaglandin E2 Stimulates Prostatic Intraepithelial Neoplasia Cell Growth through Activation of the Interleukin-6/GP130/STAT-3 Signaling Pathway , 2002 .

[31]  N. Rivard,et al.  cAMP protection of pancreatic cancer cells against apoptosis induced by ERK inhibition. , 2001, Biochemical and biophysical research communications.

[32]  M. Kay Washington,et al.  Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma Cells* , 2001, The Journal of Biological Chemistry.

[33]  L. Heasley,et al.  Autocrine and paracrine signaling through neuropeptide receptors in human cancer , 2001, Oncogene.

[34]  E. Mccleskey,et al.  Role of Phosphoinositide 3-Kinase and Endocytosis in Nerve Growth Factor-Induced Extracellular Signal-Regulated Kinase Activation via Ras and Rap1 , 2000, Molecular and Cellular Biology.

[35]  F. Sinicrope,et al.  Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. , 1999, Cancer research.

[36]  T. Fahey,et al.  Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. , 1999, Cancer research.

[37]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human lung carcinoma. , 1998, Cancer research.

[38]  D. Scollard,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. , 1998, Journal of the National Cancer Institute.

[39]  Y. Sugimoto,et al.  Molecular mechanisms of diverse actions of prostanoid receptors. , 1995, Biochimica et biophysica acta.

[40]  M. Kondo,et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.

[41]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[42]  M. Caron,et al.  G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Andre Kajdacsy-Balla,et al.  Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion , 2004, Clinical & Experimental Metastasis.

[44]  H. Reber,et al.  PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. , 2003, Biochemical and biophysical research communications.

[45]  E. Rozengurt,et al.  Gastrointestinal peptide signalling in health and disease. , 2002, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[46]  A. Levine,et al.  Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. , 2002, Biochemical and biophysical research communications.

[47]  D. Bostwick,et al.  Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma , 2000, The Prostate.

[48]  L. Marnett,et al.  Prostaglandin and thromboxane biosynthesis. , 1991, Pharmacology & therapeutics.